The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
Open accessAbstract
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Pathways of chaperone-mediated protein folding in the cytosol
Young, J. C., Agashe, V. R., Siegers, K., & Hartl, F. U. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1492 · Cited by 1,105
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Self-citationRoe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Self-citationATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo
Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4829 · Cited by 735
Self-citationIn Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis
Obermann, W. M. J., Sondermann, H., Russo, A. A., Pavletich, N. P., & Hartl, F. U. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.4.901 · Cited by 601
Trends in cancer incidence and mortality in Scotland: description and possible explanations
Swerdlow, A., dos Santos Silva, I., Reid, A., Qiao, Z., Brewster, D., & Arrundale, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.424 · Cited by 532
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Self-citationWORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Self-citationPreclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Molecular chaperones and the stress of oncogenesis
Mosser, D. D., & Morimoto, R. I. (2004) · Oncogene · doi:10.1038/sj.onc.1207529 · Cited by 502
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Self-citationSchulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
GELDANAMYCIN, A NEW ANTIBIOTIC
DEBOER, C., MEULMAN, P. A., WNUK, R. J., & PETERSON, D. H. (1970) · The Journal of Antibiotics · doi:10.7164/antibiotics.23.442 · Cited by 466
Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350
Self-citationPhase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity
Neckers, L., Schulte, T. W., & Mimnaugh, E. (1999) · Investigational New Drugs · doi:10.1023/a:1006382320697 · Cited by 301
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Powers, M. V., & Workman, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01324 · Cited by 285
Self-citationTherapeutic and diagnostic implications of Hsp90 activation
Kamal, A., Boehm, M. F., & Burrows, F. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.04.006 · Cited by 278
A New Antifungal Substance of Fungal Origin
DELMOTTE, P., & DELMOTTE-PLAQUEE, J. (1953) · Nature · doi:10.1038/171344a0 · Cited by 271
Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms
Wright, L., Barril, X., Dymock, B., Sheridan, L., Surgenor, A., Beswick, M., Drysdale, M., Collier, A., Massey, A., Davies, N., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.033 · Cited by 268
Self-citationThe Uronium/Guanidinium Peptide Coupling Reagents: Finally the True Uronium Salts
Carpino, L. A., Imazumi, H., El-Faham, A., Ferrer, F. J., Zhang, C., Lee, Y., Foxman, B. M., Henklein, P., Hanay, C., Mügge, C., et al. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020201)41:3<441::aid-anie441>3.0.co;2-n · Cited by 234
Sydor, J. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Hudak, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608372103 · Cited by 231
Hsp90: the vulnerable chaperone
Chiosis, G., Vilenchik, M., Kim, J., & Solit, D. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03245-3 · Cited by 229
Dymock, B. W., Barril, X., Brough, P. A., Cansfield, J. E., Massey, A., McDonald, E., Hubbard, R. E., Surgenor, A., Roughley, S. D., Webb, P., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050355z · Cited by 227
Self-citationCheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Self-citationXu, W., & Neckers, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2966 · Cited by 218
Ge, J., Normant, E., Porter, J. R., Ali, J. A., Dembski, M. S., Gao, Y., Georges, A. T., Grenier, L., Pak, R. H., Patterson, J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603116 · Cited by 191
Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90
He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y., Wu, N., Immormino, R. M., Gewirth, D. T., & Chiosis, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0508078 · Cited by 177
Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin
Kaur, G., Belotti, D., Burger, A. M., Fisher-Nielson, K., Borsotti, P., Riccardi, E., Thillainathan, J., Hollingshead, M. G., Sausville, E. A., & Giavazzi, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0795 · Cited by 145
Sharp, S. Y., Prodromou, C., Boxall, K. J., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K.-M. J., Kalusa, A., James, K. E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0149 · Cited by 145
Self-citationDiscovery and Development of Pyrazole-Scaffold Hsp90 Inhibitors
McDonald, E., Jones, K., Brough, P. A., Drysdale, M., & Workman, P. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812086 · Cited by 143
Self-citationDevelopment of Radicicol Analogues
Soga, S., Shiotsu, Y., Akinaga, S., & Sharma, S. V. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481859 · Cited by 143
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
Neckers, L., & Neckers, K. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.137 · Cited by 137
Egorin, M. J., Rosen, D. M., Wolff, J., Callery, P. S., Musser, S. M., & Eiseman, J. L. (1998) · PubMed · Cited by 133
Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry?
Janin, Y. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050759r · Cited by 127
Kasibhatla, S. R., Hong, K., Biamonte, M. A., Busch, D. J., Karjian, P. L., Sensintaffar, J., Kamal, A., Lough, R. E., Brekken, J., Lundgren, K., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm050752+ · Cited by 126
Sharp, S. Y., Boxall, K. J., Rowlands, M., Prodromou, C., Roe, S. M., Maloney, A., Powers, M. V., Clarke, P. A., Box, G., Sanderson, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3473 · Cited by 112
Self-citationMeli, M., Pennati, M., Curto, M., Daidone, M. G., Plescia, J., Toba, S., Altieri, D. C., Zaffaroni, N., & Colombo, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060836y · Cited by 93
A fluorescence polarization assay for inhibitors of Hsp90
Howes, R., Barril, X., Dymock, B. W., Grant, K., Northfield, C. J., Robertson, A., Surgenor, A. E., Wayne, J., Wright, L., James, K. E., et al. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2005.12.023 · Cited by 84
Self-citationBrough, P. A., Barril, X., Beswick, M., Dymock, B. W., Drysdale, M. J., Wright, L. M., Grant, K., Massey, A. J., Surgenor, A. E., & Workman, P. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.091 · Cited by 81
Self-citationWeigel, B. J., Blaney, S. M., Reid, J. M., Safgren, S. L., Bagatell, R., Kersey, J., Neglia, J. P., Ivy, S. P., Ingle, A. M., Whitesell, L. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2270 · Cited by 80
Smith, N. F., Raynaud, F. I., & Workman, P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0324 · Cited by 78
Self-citationInhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
McDonald, E., Workman, P., & Jones, K. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812004 · Cited by 75
Self-citationCrystal structures of human HSP90α-complexed with dihydroxyphenylpyrazoles
Kreusch, A., Han, S., Brinker, A., Zhou, V. W., Choi, H.-S., He, Y., Lesley, S. A., Caldwell, J. S., & Gu, X.-J. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.087 · Cited by 74
Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90
Biamonte, M. A., Shi, J., Hong, K., Hurst, D. C., Zhang, L., Fan, J., Busch, D. J., Karjian, P. L., Maldonado, A. A., Sensintaffar, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503087 · Cited by 73
Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Chiosis, G. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812013 · Cited by 62
Inhibitors of HSP90 and other chaperones for the treatment of cancer
Dymock, B. W., Drysdale, M. J., McDonald, E., & Workman, P. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.6.837 · Cited by 46
Self-citation
Cited by
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedDrug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Self-citationBiophysics in drug discovery: impact, challenges and opportunities
Renaud, J.-P., Chung, C.-W., Danielson, U. H., Egner, U., Hennig, M., Hubbard, R. E., & Nar, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.123 · Cited by 382
Self-citationJackson, S. E. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_356 · Cited by 338
Metadata
- Authors
- Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., Dymock, B., Eccles, S. A., Finch, H., Fink, A., Hayes, A., Howes, R., Hubbard, R. E., James, K., Jordan, A. M., Lockie, A., Martins, V., Massey, A., Matthews, T. P., McDonald, E., Northfield, C. J., Pearl, L. H., Prodromou, C., Ray, S., Raynaud, F. I., Roughley, S. D., Sharp, S. Y., Surgenor, A., Walmsley, D. L., Webb, P., Wood, M., Workman, P., & Wright, L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-11-20
- Volume
- 51
- Issue
- 2
- Pages
- 196-218
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1999715990
- Cited by
- 444
- References
- 49
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
